Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267722 · ClinicalTrials.gov registry record · Phase 2
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
A Phase 2 study, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00267722 is a Phase 2 study that has completed, run by Facet Biotech. The registered enrollment target is 18 participants.
The verdict
NCT00267722, a Phase 2 study, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat moderate to severe inflammatory, nonstricturing, nonpenetrating Crohn's disease. The research is being conducted at up to 5 clinical research sites in the US and Europe and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site up to 17 months. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work. Visilizumab is a humanized antibody (antibodies are proteins that are normally made by the immune system to help defend the body from infections and other foreign substances) that is directed against T cells. Visilizumab selectively attacks problematic T cells and, in doing so, it may prevent them from causing inflammation. Visilizumab has also been observed to have a suppressive effect on the body's immune system (system in the body that reacts to foreign or occasionally one's own proteins).
Interventions
- DRUG Visilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267722
The ClinicalTrials.gov registry entry for NCT00267722 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Visilizumab is the first listed.
NCT00267722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267722 about?
NCT00267722 is a clinical study titled "Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease". The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat moderate to severe inflammatory, nonstricturing, nonpenetrating Crohn's disease. The research is being conducted at up to 5 clinical research sites in the US and Europe and is open to both men a...
What is the current status of trial NCT00267722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2005-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00267722?
The interventions under investigation include: Visilizumab (DRUG).
Who is sponsoring clinical trial NCT00267722?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.